Current status of hepatocellular carcinoma treatment in Japan: Case study and discussion-voting system

Clinical Drug Investigation

Volumn 32, Issue SUPPL. 2, 2012, Pages 37-51

  Kudo, Masatoshi ^a   Tateishi, Ryosuke ^b   Yamashita, Tatsuya ^c   Ikeda, Masafumi ^d   Furuse, Junji ^e   Ikeda, Kenji ^f   Kokudo, Norihiro ^g   Izumi, Namiki ^h   Matsui, Osamu ⁱ  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^e KYORIN UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f TORANOMON HOSPITAL   (Japan)

^g UNIVERSITY OF TOKYO   (Japan)

^h MUSASHINO RED CROSS HOSPITAL   (Japan)

ⁱ KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROPYRIMIDINE; SORAFENIB;

ADVANCED CANCER; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CHEMOEMBOLIZATION; CLINICAL PRACTICE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG TOLERABILITY; HUMAN; JAPAN; LIVER CELL CARCINOMA; LIVER FUNCTION; MEDICAL SOCIETY; METASTASIS; PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SURVIVAL; SURVIVAL TIME; TREATMENT DURATION; TREATMENT FAILURE; TREATMENT RESPONSE;

ANTINEOPLASTIC AGENTS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; HUMANS; JAPAN; LIVER NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; PYRIDINES; TIME FACTORS;

EID: 84864642779     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.2165/1163024-S0-000000000-00000     Document Type: Review

References (27)

1. Bayer Healthcare Pharmaceuticals. Nexavar approved in Japan for the treatment of advanced liver cancer. 2009 [cited; Available from: http://press.bayerhealthcare.com/en/press/auth/news-details-page.php/13182/ 2009-0239
2. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma. Hepatology International 2010; 4 (2): 439-74
3. The Japan Society of Hepatology. The Japanese HCC Clinical Practice Guideline. Treatment algorithmfor hepatocellular carcinoma. Hepatology Research 2010; 40 (Suppl. 1): 8-9
4. Kudo M, Izumi N, Kokudo N, et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011; 29 (3): 339-64
5. Bruix J, Sherman M. AASLD Practice Guideline: Management of Hepatocellular Carcinoma: An Update. Available at http://www.aasld.org/ practiceguidelines/Documents/Bookmarked%20Practice%20Guidelines/HCCUpdate2010. pdf (Accessed 14 Nov 2010). Hepatology 2010; July: 1-35
6. Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362 (9399): 1907-17 (Pubitemid 37518510)
7. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359 (4): 378-90
8. Sherman M, Mazzaferro V, Amadori D, et al. Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma and vascular invasion or extrahepatic spread: A subanalysis from the SHARP trial. J Clin Oncol 2008; 26 (May 20 suppl): abstract 4584
9. Kudo M, Ueshima K. Positioning of a molecular-targeted agent, sorafenib, in the treatment algorithm for hepatocellular carcinoma and implication of many complete remission cases in Japan. Oncology 2010 Jul; 78 (Suppl. 1): 154-66
10. Furuse J, Okusaka T, Kaneko S, et al. Phase I/II study of the pharmacokinetics, safety and efficacy of S-1 in patients with advanced hepatocellular carcinoma. Cancer Sci 2010; 101 (12): 2606-11
11. Llovet JM, Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 2008 Oct; 48 (4): 1312-27
12. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32 (6): 1224-9
13. Shiina S, Teratani T, Obi S, et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 2005; 129 (1): 122-30 (Pubitemid 41002049)
14. Charnsangavej C, Chuang VP, Wallace S, et al. Angiographic classification of hepatic arterial collaterals. Radiology 1982; 144 (3): 485-94 (Pubitemid 12093902)
15. Ikeda K, Kumada H, Saitoh S, et al. Effect of repeated transcatheter arterial embolization on the survival time in patients with hepatocellular carcinoma. An analysis by the Cox proportional hazard model. Cancer 1991; 68 (10): 2150-4
16. Kawamura Y, Ikeda K, Hirakawa M, et al. Efficacy of platinum analogue for advanced hepatocellular carcinoma unresponsive to transcatheter arterial chemoembolization with epirubicin. Hepatol Res 2009; 39 (4): 346-54
17. Maeda N, Osuga K, Higashihara H, et al. Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-lipiodol emulsion. Cardiovasc Intervent Radiol 2011 Feb; 35 (1): E82-9
18. Galle P, Blanc J, Van Laethem J-L, et al. Efficacy and safety of sorafenib in patients with hepatocellular carcinoma and prior anti-tumor therapy: a subanalysis from the SHARP trial. 43rd annual meeting of the European Association for the Study of the Liver (EASL 2008) Milan, Italy April 23-27, 2008 2008 [cited; Available from: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi? cmd=Retrieve&db=PubMed&dopt=Citation&list-uids=18817997
19. Iwasa S, Ikeda M, Okusaka T, et al. Transcatheter arterial infusion chemotherapy with a fine-powder formulation of cisplatin for advanced hepatocellular carcinoma refractory to transcatheter arterial chemoembolization. Jpn J Clin Oncol 2011 Jun; 41 (6): 770-5
20. Bayer HealthCare Pharmaceuticals Inc. Sorafenib. Prescribing information. Available at http://www.nexavar.com/html/download/Nexavar-PI.pdf Accessed 2 December 2010. 2009:
21. Ueshima K, Kudo M, Tanaka M, et al. Session 11-05, Phase I study of sorafenib in combination with low-dose cisplatin and fluorouracil intra-arterail infusion chemotherapy.Osaka, Japan: The 2nd Asia-Pacific Primary Liver Cancer Expert Meeting-A Bridge to Consensus on HCC Management, 2011
22. Kudo M. Molecular Targeted Therapy of Hepatocellular Carcinoma. Tokyo: Arc Media, 2010
23. Kudo M, Imanaka K, Chida N, et al. Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 2011; (14): 2117-27
24. Vagefi PA, Hirose R. Downstaging of hepatocellular carcinoma prior to liver transplant: is there a role for adjuvant sorafenib in locoregional therapy? J Gastrointest Cancer 2010; 41 (4): 217-20
25. Saab S, McTigue M, Finn RS, et al. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy. Exp Clin Transplant 2010; 8 (4): 307-13
26. Yeganeh M, Finn RS, Saab S. Apparent remission of a solitary metastatic pulmonary lesion in a liver transplant recipient treated with sorafenib. Am J Transplant 2009; 9 (12): 2851-4
27. Bhoori S, Toffanin S, Sposito C, et al. Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle. J Hepatol 2010; 52 (5): 771-5